(Circulation. 2000;102:2335.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Chlamydia pneumoniae, Herpes Simplex Virus Type 1, and Cytomegalovirus and Incident Myocardial Infarction and Coronary Heart Disease Death in Older Adults
The Cardiovascular Health Study
Presented in part at the American Heart Association Council on Epidemiology and Prevention Scientific Sessions, Santa Fe, NM, March 1998.
From the Departments of Medicine (D.S.S., B.M.P., L.C.), Epidemiology (D.S.S., B.M.P., S.M.S., J.T.G.), Health Services (B.M.P.), Pathobiology (J.T.G., S.P.W.), Biostatistics (R.A.K.), and Laboratory Medicine (L.C., R.A.), University of Washington and Fred Hutchinson Cancer Research Center (S.M.S., L.C.) (Seattle); Department of Epidemiology (L.H.K.), University of Pittsburgh, Pittsburgh, Pa; and Department of Pathology (R.P.T.), University of Vermont (Burlington).
Background—Whether serological evidence of prior infection with Chlamydia pneumoniae, herpes simplex virus type 1 (HSV-1), and cytomegalovirus (CMV) is associated with myocardial infarction (MI) and coronary heart disease (CHD) death remains a source of controversy.
Methods and Results—We conducted a nested case-control study
among participants in the Cardiovascular Health Study,
a cohort study of persons aged 
65 years. Cases experienced an
incident MI and CHD death (n=213). Control subjects were matched to
cases by age, sex, clinic, year of enrollment, and month of blood draw
(n=405). Serum was analyzed for IgG antibodies to C
pneumoniae, HSV-1, and CMV. After adjustment for other risk
factors, the risk of MI and CHD death was associated with the presence
of IgG antibodies to HSV-1 (odds ratio [OR] 2.0, 95% CI 1.1 to 3.6)
but was not associated with the presence of IgG antibodies to either
C pneumoniae (OR 1.1, 95% CI 0.7 to 1.8) or CMV (OR
1.2, 95% CI 0.7 to 1.9). Although there was little association with
low to moderate C pneumoniae antibody titers (
1:512),
high-titer (1:1024) C pneumoniae antibody was associated
with an increased risk (OR 2.2, 95% CI 1.1 to 4.4).
Conclusions—Among older adults, the presence of IgG antibodies to HSV-1 was associated with a 2-fold increase in the risk of incident MI and CHD death. For C pneumoniae, only high-titer IgG antibodies were associated with an increased risk of MI and CHD death. The presence of IgG antibodies to CMV was not associated with risk among the elderly.
Key Words: bacteria • viruses • myocardial infarction • coronary heart disease • aging
This article has been cited by other articles:
 |
|
 |
|
  B. Reinhardt, T. Mertens, U. Mayr-Beyrle, H. Frank, A. Luske, K. Schierling, and J. Waltenberger HCMV infection of human vascular smooth muscle cells leads to enhanced expression of functionally intact PDGF {beta}-receptor Cardiovasc Res, July 1, 2005; 67(1): 151 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Sheehan, P M Kearney, S O Sullivan, C Mongan, E Kelly, and I J Perry Acute coronary syndrome and chronic infection in the Cork coronary care case-control study Heart, January 1, 2005; 91(1): 19 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. O'Connor, M. W. Dunne, M. A. Pfeffer, J. B. Muhlestein, L. Yao, S. Gupta, R. J. Benner, M. R. Fisher, and T. D. Cook Azithromycin for the Secondary Prevention of Coronary Heart Disease Events: The WIZARD Study: A Randomized Controlled Trial JAMA, September 17, 2003; 290(11): 1459 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Holly and P. M. Bracci Population-based Study of Non-Hodgkin Lymphoma, Histology, and Medical History among Human Immunodeficiency Virus-negative Participants in San Francisco Am. J. Epidemiol., August 15, 2003; 158(4): 316 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Agmon, B. K. Khandheria, I. Meissner, T. M. Petterson, W. M. O'Fallon, T. J. H. Christianson, D. O. Wiebers, T. F. Smith, J. M. Steckelberg, and A. J. Tajik Lack of association between Chlamydia pneumoniae seropositivity and aortic atherosclerotic plaques: A Population-Based transesophageal echocardiographic study J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1482 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Hill, G. Gridley, S. Cnattingius, L. Mellemkjaer, M. Linet, H.-O. Adami, J. H. Olsen, O. Nyren, and J. F. Fraumeni Jr Mortality and Cancer Incidence Among Individuals With Down Syndrome Arch Intern Med, March 24, 2003; 163(6): 705 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Smieja, J. Gnarpe, E. Lonn, H. Gnarpe, G. Olsson, Q. Yi, V. Dzavik, M. McQueen, S. Yusuf, and for the Heart Outcomes Prevention Evaluation (HOPE Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study Circulation, January 21, 2003; 107(2): 251 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.A. Erkens, O.H. Klungel, R.M.C. Herings, R.P. Stolk, J.A. Spoelstra, D.E. Grobbee, and H.G.M. Leufkens Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients Eur. Heart J., October 2, 2002; 23(20): 1575 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Wallby, B Janerot-Sjoberg, T Steffensen, and M Broqvist T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves Heart, October 1, 2002; 88(4): 348 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prasad, J. Zhu, J. P.J. Halcox, M. A. Waclawiw, S. E. Epstein, and A. A. Quyyumi Predisposition to Atherosclerosis by Infections: Role of Endothelial Dysfunction Circulation, July 9, 2002; 106(2): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Kerrigan, I. Douglas, A. Wray, J. Heath, M. F. Byrne, D. Fitzgerald, and D. Cox A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation Blood, June 28, 2002; 100(2): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Alber, P. Vallance, and K. L. Powell Enhanced Atherogenesis Is Not an Obligatory Response to Systemic Herpesvirus Infection in the ApoE-Deficient Mouse: Comparison of Murine {gamma}-Herpesvirus-68 and Herpes Simplex Virus-1 Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 793 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miura, H. Nakagawa, and P. Greenland Invited Commentary: Height-Cardiovascular Disease Relation: Where to Go from Here? Am. J. Epidemiol., April 15, 2002; 155(8): 688 - 689. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stollberger and J. Finsterer Role of Infectious and Immune Factors in Coronary and Cerebrovascular Arteriosclerosis Clin. Vaccine Immunol., March 1, 2002; 9(2): 207 - 215. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boman and M. R. Hammerschlag Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies Clin. Microbiol. Rev., January 1, 2002; 15(1): 1 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Blake and P. M. Ridker Novel Clinical Markers of Vascular Wall Inflammation Circ. Res., October 26, 2001; 89(9): 763 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Rupprecht, S. Blankenberg, C. Bickel, G. Rippin, G. Hafner, W. Prellwitz, W. Schlumberger, and J. Meyer Impact of Viral and Bacterial Infectious Burden on Long-Term Prognosis in Patients With Coronary Artery Disease Circulation, July 3, 2001; 104(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah Link Between Infection and Atherosclerosis: Who Are The Culprits: Viruses, Bacteria, Both, or Neither? Circulation, January 2, 2001; 103(1): 5 - 6. [Full Text] [PDF]
|
|